Letrozol Devatis

Letrozole, the active ingredient in Letrozol Devatis, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can fuel tumor growth.

GNH USA supplies Letrozol Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support throughout the order lifecycle.

Letrozole acts on the estrogen synthesis pathway and is indicated for several breast cancer treatment settings.

- Advanced hormone receptor‑positive breast cancer: slows disease progression and may extend survival. - Post‑surgical adjuvant breast cancer: reduces risk of cancer recurrence after tumor removal. - Metastatic breast cancer in postmenopausal women: helps control tumor growth and improve disease control.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects: - Severe bone loss or osteoporosis: increased fracture risk. - Elevated liver enzymes: potential liver injury. - Cardiovascular events: blood clots or heart problems. - Severe allergic reaction: rash, swelling, breathing difficulty.

When prescribing Letrozol Devatis, clinicians should consider several safety measures.

- Monitor bone health: assess calcium, vitamin D, and bone density regularly. - Check liver function: perform baseline and periodic liver enzyme tests. - Evaluate cardiovascular risk: review history of thromboembolism before initiating therapy. - Contraindicated in pregnancy: letrozole is pregnancy category X and must not be used by pregnant women. - Counsel on hot flashes: inform patients they may experience temperature‑related symptoms and discuss management strategies. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Letrozol Devatis can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: reduces letrozole efficacy. - Tamoxifen: antagonistic effect on estrogen suppression. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): may raise letrozole levels. - Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.